Minocycline
- Generic Name
- Minocycline
- Brand Names
- Amzeeq, Arestin, Dynacin, Minocin, Minolira, Solodyn, Ximino, Zilxi
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27N3O7
- CAS Number
- 10118-90-8
- Unique Ingredient Identifier
- FYY3R43WGO
- Background
Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.
Minocycline was granted FDA approval on 30 June 1971.
- Indication
Oral and topical minocycline are indicated to treat inflammatory lesions of acne vulgaris. Subgingival microspheres are indicated as an adjunct treatment in the reduction of pocket depth in adults with periodontitis. Oral and intravenous formulations are indicated to treat infections of susceptible microorganisms. These include rickettsiae, Mycoplasma pneumoniae, Chlamydia trachomatis, Chlamydophila psittaci, Chlamydia trachomatis, Ureaplasma urealyticum, Borrelia recurrentis, Haemophilus ducreyi, Yersinia pestis, Francisella tularensis, Vibrio cholerae, Campylobacter fetus, Brucella species, Bartonella bacilliformis, Klebsiella granulomatis, Escherichia coli, Enterobacter aerogenes, Shigella species, Acinetobacter species, Haemophilus influenzae, and Kelbsiella species.
- Associated Conditions
- Bartonellosis, Brucellosis, Campylobacter fetus, Chancroid, Cholera (Disorder), Conjunctivitis, Inclusion, Granuloma Inguinale, Lymphogranuloma Venereum, Nongonococcal urethritis, Periodontitis, Plague, Psittacosis, Q Fever, Relapsing Fever, Respiratory Tract Infections (RTI), Rickettsia Infections, Rickettsialpox, Rocky Mountain Spotted Fever, Trachoma, Tularemia, Typhus infections, Inflammatory lesions
A Comparative Bioavailability Study of DFD-29 Capsules 40 mg Versus SOLODYN® Tablets 105 mg, Under Fasting & Fed Conditions in Healthy Adult Human Subjects
- Conditions
- Pharmacokinetics
- Interventions
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Journey Medical Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT05452785
- Locations
- 🇨🇦
CRO, Québec, Canada
Minocycline Efficacy in Improving Neurological Outcome of Patients Who Undergo Endovascular Revascularization for Acute Ischemic Stroke
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- State University of New York at Buffalo
- Target Recruit Count
- 134
- Registration Number
- NCT05367362
A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)
- Conditions
- Papulopustular Rosacea
- Interventions
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Journey Medical Corporation
- Target Recruit Count
- 330
- Registration Number
- NCT05343455
- Locations
- 🇺🇸
Clinical Trial Site 14, Miami, Florida, United States
🇺🇸Clinical Trial Site 05, Miramar, Florida, United States
🇺🇸Clinical Trial Site 08, Clarksville, Indiana, United States
A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
- Conditions
- Papulopustular Rosacea
- Interventions
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Journey Medical Corporation
- Target Recruit Count
- 323
- Registration Number
- NCT05296629
- Locations
- 🇺🇸
Clinical Trial Site 25, San Diego, California, United States
🇺🇸Clinical Trial Site 13, Houston, Texas, United States
🇺🇸Clinical Trial Site 02, Indianapolis, Indiana, United States
Efficacy of Oral Minocycline (Solodyn) and Oral Minocycline (Solodyn) Plus Azelaic Acid (Finacea) for Acne Rosacea
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- Dermatology Specialists Research
- Target Recruit Count
- 60
- Registration Number
- NCT05014906
- Locations
- 🇺🇸
Dermatology Specialists, Louisville, Kentucky, United States
To Evaluate the Efficacy and Safety of Minocycline Hydrochloride Foam in the Treatment of Moderate-to-severe Acne Vulgaris
- First Posted Date
- 2021-07-14
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Cutia Therapeutics (Shanghai) Co., Ltd
- Target Recruit Count
- 372
- Registration Number
- NCT04960930
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳China-Japan Friendship Hospital, Beijin, Beijin, China
🇨🇳Dermatology Hosptial of Southern Medical University, Yuexiu, Guangdong, China
A Companion Treatment Study for Patients With Moderate to Severe Acne Vulgaris
- First Posted Date
- 2021-06-28
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Edward Lain, MD
- Target Recruit Count
- 31
- Registration Number
- NCT04940767
- Locations
- 🇺🇸
Austin Institute for Clinical Research, Inc., Pflugerville, Texas, United States
Minocycline for Aneurysmal Subarachnoid Hemorrhage (MASH)
- Conditions
- Aneurysm, RupturedDelayed Cerebral IschemiaBlood Brain Barrier DefectVasospasm, Intracranial
- First Posted Date
- 2021-05-06
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 20
- Registration Number
- NCT04876638
- Locations
- 🇺🇸
University of Southern California Department of Neurosurgery, Los Angeles, California, United States
A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea
- Conditions
- Facial Papulopustular Rosacea
- Interventions
- Drug: Vehicle foam
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2021-01-07
- Lead Sponsor
- Vyne Therapeutics Inc.
- Target Recruit Count
- 771
- Registration Number
- NCT04608500
- Locations
- 🇺🇸
Foamix Investigational Site #247, Hialeah, Florida, United States
🇺🇸Foamix Investigational Site #252, Hialeah, Florida, United States
🇺🇸Foamix Investigational Site # 228, Knoxville, Tennessee, United States
The Effect of Minocycline and N-acetylcysteine for the Treatment of Fibromyalgia
- Conditions
- Fibromyalgia
- Interventions
- Drug: Placebo followed by minocycline (200 mg daily) and NAC (1200 mg daily)
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 14
- Registration Number
- NCT04594733
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.